Liraglutide: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{Editor Help}} | {{Editor Help}} | ||
==Overview== | |||
'''Liraglutide''' is a glucagon-like peptide-1 ([[GLP-1]]) analog that is being developed by [[Novo Nordisk]] for the treatment of [[type 2 diabetes]]. | '''Liraglutide''' is a glucagon-like peptide-1 ([[GLP-1]]) analog that is being developed by [[Novo Nordisk]] for the treatment of [[type 2 diabetes]]. | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 22:25, 6 March 2009
WikiDoc Resources for Liraglutide |
Articles |
---|
Most recent articles on Liraglutide Most cited articles on Liraglutide |
Media |
Powerpoint slides on Liraglutide |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Liraglutide at Clinical Trials.gov Clinical Trials on Liraglutide at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Liraglutide
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Liraglutide Discussion groups on Liraglutide Patient Handouts on Liraglutide Directions to Hospitals Treating Liraglutide Risk calculators and risk factors for Liraglutide
|
Healthcare Provider Resources |
Causes & Risk Factors for Liraglutide |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog that is being developed by Novo Nordisk for the treatment of type 2 diabetes.